Log In
Print
BCIQ
Print
Print this Print this
 

mavrilimumab (formerly CAM-3001)

  Manage Alerts
Collapse Summary General Information
Company AstraZeneca plc
DescriptionHuman mAb targeting the alpha receptor of GM-CSF
Molecular Target Granulocyte macrophage colony-stimulating factor (GM-CSF) receptor (CSF2RA) (GMR) (CD116)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase II
Standard IndicationRheumatoid arthritis (RA)
Indication DetailsTreat moderate to severe rheumatoid arthritis (RA)
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today